Coherus Oncology Inc (NAS:CHRS)
$ 1.45 -0.020 (-1.36%) Market Cap: 223.66 Mil Enterprise Value: 96.61 Mil PE Ratio: 0.87 PB Ratio: 2.84 GF Score: 42/100

Coherus Oncology Inc at TD Cowen Healthcare Conference Transcript

Mar 04, 2026 / 04:50PM GMT
Release Date Price: $1.76 (+6.67%)
Michaek Nedelcovych
TD Cowen - Analyst

Great. Welcome everybody to the coherent session. Thanks so much for your time. My name is Mike Nedelcovych. I'm part of the TDcom research team. I'm very pleased to be joined by Denny, who's the CEO of Coherence Psychology and Teresa, the head of research.

Questions & Answers

Michaek Nedelcovych
TD Cowen - Analyst

I, I'll start with a big picture picture question. And it's one that's very important to the company. You've affected a very impressive strategic transition to an innovative oncology biotech, and you have an approved drug in Loc Torzi, which is a relatively unique position to be in. Can you describe the rationale behind that shift and what it's taken you to get here?

Dennis Lanfear
Coherus Oncology Inc - Chairman of the Board, President, Chief Executive Officer

No, thanks for the question, Michael, and thank you to the bank and our long standing relationship for your, invitation to say. So, it's been a lot of fun. I think we managed to move, pretty

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot